Entera Bio Ltd. (ENTX) vs Insight Molecular Diagnostics Inc. (IMDX)
A side-by-side comparison of Entera Bio Ltd. and Insight Molecular Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ENTX
Entera Bio Ltd.
$2.59HealthcareDelayed quote: Oct 6, 2026, 2:39 PM EDT
IMDX
Insight Molecular Diagnostics Inc.
$3.47HealthcareDelayed quote: Oct 6, 2026, 2:39 PM EDT
Total return — ENTX vs IMDX
growth of $100 · dividends reinvested · last 8yENTX -58.3% (-10.4%/yr)IMDX -93.2% (-28.5%/yr)ENTX compounded faster over this window
Log scale — wide-divergence pair
ENTX IMDX
ENTX vs IMDX: by the numbers
- •ENTX is the larger company ($127M vs $112M market cap).
- •Both run net losses; IMDX's is the smaller (-2955.63% vs -27235.71% net margin).
Metrics side by side
Valuation
| Metric | ENTX | IMDX |
|---|---|---|
| P/S ratio | N/A | 67.00 |
| P/B ratio | 17.54 | N/A |
Profitability
| Metric | ENTX | IMDX |
|---|---|---|
| Gross margin | 0.00% | 11.17% |
| Operating margin | -27450.00% | -754.08% |
| Net margin | -27235.71% | -2955.63% |
| ROE | -234.42% | N/A |
| ROIC | -82.87% | -223.06% |
Growth (annualized)
| Metric | ENTX | IMDX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 27.24% |
| Total return CAGR (5Y) | -10.57% | -44.39% |
Frequently asked
- How have ENTX and IMDX total returns compared?
- Over the past 5 years, ENTX delivered -10.57% and IMDX delivered -44.39% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Entera Bio ROEInsight Molecular Diagnostics ROEEntera Bio operating marginInsight Molecular Diagnostics operating marginEntera Bio revenue growthInsight Molecular Diagnostics revenue growthEntera Bio free cash flowInsight Molecular Diagnostics free cash flow
Entera Bio & Insight Molecular Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.